{"id":"low-dose-cytarabine-ldac","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Mucositis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cytarabine is a cytidine analog that is phosphorylated intracellularly and incorporated into DNA, disrupting DNA synthesis and causing cell death. At low doses, it preferentially affects myelodysplastic and leukemic cells while sparing normal hematopoiesis to some degree. The mechanism involves both direct cytotoxicity and potential differentiation-promoting effects in certain myeloid malignancies.","oneSentence":"Low-dose cytarabine is a nucleoside analog that inhibits DNA synthesis by incorporating into DNA and blocking cell division, primarily affecting rapidly dividing hematopoietic cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:34.124Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myeloid leukemia (AML) in elderly or unfit patients"},{"name":"Myelodysplastic syndrome (MDS)"}]},"trialDetails":[{"nctId":"NCT01515527","phase":"PHASE2","title":"Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-02-07","conditions":"Leukemia","enrollment":160},{"nctId":"NCT06001788","phase":"PHASE1","title":"Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2024-02-22","conditions":"AML, AML With Mutated NPM1, Hematologic Malignancy","enrollment":171},{"nctId":"NCT04848974","phase":"PHASE1, PHASE2","title":"Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-06-11","conditions":"Secondary Acute Myeloid Leukemia","enrollment":37},{"nctId":"NCT03586609","phase":"PHASE2","title":"Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-10-25","conditions":"Acute Myeloid Leukemia","enrollment":145},{"nctId":"NCT04777916","phase":"","title":"Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)","status":"RECRUITING","sponsor":"Acute Leukemia French Association","startDate":"2022-04-14","conditions":"Acute Myeloid Leukemia (AML)","enrollment":5000},{"nctId":"NCT03069352","phase":"PHASE3","title":"A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy","status":"COMPLETED","sponsor":"AbbVie","startDate":"2017-05-23","conditions":"Acute Myeloid Leukemia (AML)","enrollment":211},{"nctId":"NCT04891757","phase":"PHASE1","title":"FHD-286 as Monotherapy or Combination Therapy in Subjects With Advanced Hematologic Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Foghorn Therapeutics Inc.","startDate":"2021-06-14","conditions":"Advanced Hematologic Malignancy, Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":144},{"nctId":"NCT02577406","phase":"PHASE3","title":"An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation","status":"COMPLETED","sponsor":"Celgene","startDate":"2015-12-30","conditions":"Leukemia, Myeloid, Isocitrate Dehydrogenase","enrollment":319},{"nctId":"NCT02038777","phase":"PHASE1","title":"A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-03-25","conditions":"Acute Myeloid Leukemia","enrollment":48},{"nctId":"NCT02920008","phase":"PHASE3","title":"Phase 3 Randomized, Open-Label Study of Guadecitabine vs Treatment Choice in Previously Treated Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2017-03-16","conditions":"Acute Myeloid Leukemia","enrollment":302},{"nctId":"NCT04113616","phase":"PHASE1, PHASE2","title":"An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)","status":"TERMINATED","sponsor":"Kartos Therapeutics, Inc.","startDate":"2019-09-25","conditions":"Relapsed or Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Secondary to Myeloproliferative Neoplasms (MPN)","enrollment":70},{"nctId":"NCT02461537","phase":"PHASE3","title":"Impact of Remission Induction Chemotherapy Prior to Allogeneic SCT in Relapsed and Poor-response Patients With AML","status":"COMPLETED","sponsor":"DKMS gemeinnützige GmbH","startDate":"2015-09-17","conditions":"Acute Myeloid Leukemia","enrollment":281},{"nctId":"NCT00804856","phase":"PHASE2","title":"Phase I/IIa Trial to Investigate BI 6727 (Volasertib) as Monotherapy or in Combination With Cytarabine in Acute Myeloid Leukaemia","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-11-27","conditions":"Leukemia, Myeloid, Acute","enrollment":180},{"nctId":"NCT02575963","phase":"PHASE1, PHASE2","title":"Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients","status":"COMPLETED","sponsor":"Actinium Pharmaceuticals","startDate":"2012-10","conditions":"AML","enrollment":40},{"nctId":"NCT03634228","phase":"PHASE1, PHASE2","title":"Milademetan Tosylate and Low-Dose Cytarabine With or Without Venetoclax in Treating Participants With Recurrent or Refractory Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-12-17","conditions":"Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":16},{"nctId":"NCT04687761","phase":"PHASE1, PHASE2","title":"Clinical Trial to Assess the Safety and Tolerability of the Combination of Low-dose Cytarabine or Azacitidine Plus Venetoclax and Quizartinib in Newly Diagnosed AML Patients Aged Equal or More Than 60 Years Old","status":"UNKNOWN","sponsor":"PETHEMA Foundation","startDate":"2020-11-04","conditions":"Leukemia, Myeloid, Acute, De Novo, Age More 60yr","enrollment":84},{"nctId":"NCT02287233","phase":"PHASE1, PHASE2","title":"A Study Evaluating Venetoclax in Combination With Low-Dose Cytarabine in Treatment-Naïve Participants With Acute Myelogenous Leukemia","status":"COMPLETED","sponsor":"AbbVie","startDate":"2014-12-31","conditions":"Acute Myelogenous Leukemia, AML","enrollment":94},{"nctId":"NCT04509622","phase":"PHASE3","title":"A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"AbbVie","startDate":"2020-10-05","conditions":"Acute Myeloid Leukemia (AML)","enrollment":14},{"nctId":"NCT03459859","phase":"PHASE1","title":"Pevonedistat and Low Dose Cytarabine in Adult Patients With AML and MDS","status":"COMPLETED","sponsor":"Justin Watts, MD","startDate":"2018-05-21","conditions":"Acute Myelogenous Leukemia, AML, Advanced Myelodysplastic Syndromes","enrollment":12},{"nctId":"NCT02305563","phase":"PHASE1, PHASE2","title":"An Investigational Immuno-therapy Study of Ulocuplumab in Combination With Low Dose Cytarabine in Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"TERMINATED","sponsor":"Bristol-Myers Squibb","startDate":"2015-01-27","conditions":"Leukemia","enrollment":70},{"nctId":"NCT01159028","phase":"PHASE1","title":"Clinical Trial of BP1001 (L-Grb-2 Antisense Oligonucleotide) in CML, AML, ALL & MDS","status":"COMPLETED","sponsor":"Bio-Path Holdings, Inc.","startDate":"2010-06","conditions":"Recurrent Adult Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome","enrollment":60},{"nctId":"NCT01546038","phase":"PHASE2","title":"A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-06-27","conditions":"Acute Myeloid Leukemia","enrollment":255},{"nctId":"NCT00952588","phase":"PHASE2, PHASE3","title":"Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-07","conditions":"Acute Myeloid Leukemia","enrollment":74},{"nctId":"NCT01272245","phase":"PHASE2","title":"Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2011-07","conditions":"Leukemia","enrollment":36},{"nctId":"NCT02084563","phase":"PHASE2","title":"Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms","status":"COMPLETED","sponsor":"Hospital Israelita Albert Einstein","startDate":"2012-10","conditions":"Acute Myeloid Leukemia, Myeloproliferative Neoplasms, Myelodysplastic Syndromes","enrollment":455},{"nctId":"NCT00136084","phase":"PHASE3","title":"Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia","status":"COMPLETED","sponsor":"St. Jude Children's Research Hospital","startDate":"2002-08","conditions":"Leukemia, Myelocytic, Acute","enrollment":238},{"nctId":"NCT00926731","phase":"PHASE1","title":"Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-06","conditions":"Acute Myeloid Leukemia","enrollment":4}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"ACUTE MYELOID LEUKAEMIA RECURRENT"},{"count":1,"reaction":"DEATH"},{"count":1,"reaction":"ENTEROCOCCAL BACTERAEMIA"},{"count":1,"reaction":"ESCHERICHIA BACTERAEMIA"},{"count":1,"reaction":"FEBRILE NEUTROPENIA"},{"count":1,"reaction":"NEUTROPENIA"},{"count":1,"reaction":"OFF LABEL USE"},{"count":1,"reaction":"THROMBOCYTOPENIA"}],"_approvalHistory":[],"publicationCount":151,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Low-dose cytarabine (LDAC)","genericName":"Low-dose cytarabine (LDAC)","companyName":"Celgene","companyId":"celgene","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Low-dose cytarabine is a nucleoside analog that inhibits DNA synthesis by incorporating into DNA and blocking cell division, primarily affecting rapidly dividing hematopoietic cells. Used for Acute myeloid leukemia (AML) in elderly or unfit patients, Myelodysplastic syndrome (MDS).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}